Dailymirror.news,Ahmedabad, May 21st, 2026: Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and full year ended March 31, 2026.

Q4 and FY2026 Financial Performance Summary (Consolidated):

Particulars (INR Cr)Q4 FY26Q4 FY25YoY (%)FY2026FY2025YoY (%)
Revenue from Operations7577057%3,1292,8948%
       
Gross Profit5715357%2,3342,1807%
       
EBITDA2742528%1,1201,01710%
EBITDA Margin (%)36.2%35.8% 35.8%35.2% 
       
Profit After Tax (PAT)279102173%64837573%
PAT Margin (%)36.9%14.5%–20.7%12.9% 


Q4 and FY2026 Key Financial Highlights:

ఇదీ చదవండి :ఫెలోషిప్ ,ట్రాన్స్‌లేషనల్ పరిశోధనలకు మద్దతుతో గీతమ్ (GITAM)పీహెచ్‌డీ అడ్మిషన్ల నోటిఫికేషన్2026 విడుదల

Read this also..GITAM Opens Ph.D. Admissions 2026 with Fellowship and Translational Research Support..

  • DBF business revenue growth of 12% YoY in Q4 and 11% YoY in FY26 – EBIDTA margin 37%
  • Consolidated Revenue growth 7% YoY in Q4 and 8% YoY in FY26 – EBIDTA margin 36%
  • Consolidated Q4 PAT Rs. 279 Cr with a 174% growth, FY26 PAT Rs. 648 Cr, with a 73% growth
  • Net debt as of March 31, 2026, stood at Rs. 2,255 Cr

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, “Our Domestic Formulations business delivered a 11% revenue growth in FY26 with a 12% EBIDTA growth and industry leading EBIDTA margin of 37%. Our Insulins franchise has outpaced market growth by 5x in FY26 with a market share expansion from 12% to 16%.

Our GLP brand Sundae has gotten off to a strong start, which reflects the present standing of the company in the Injectable Diabesity space. Sundae ranks #1 by volume (among injectables) in its very first month of launch, which validates our thesis of being able to leverage our Insulins platform to secure a strong position in the GLP segment.”